

# John Dillon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3431796/john-dillon-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185  
papers

7,180  
citations

39  
h-index

79  
g-index

208  
ext. papers

8,604  
ext. citations

6.2  
avg, IF

5.66  
L-index

#	Paper	IF	Citations
185	Hepatitis B, Hepatitis C and Liver Disease: A Review for the Dental Practitioner. <i>Dental Update</i> , <b>2022</b> , 49, 26-30	0.3	0
184	Competing Risk Bias in Prognostic Models Predicting Hepatocellular Carcinoma Occurrence: Impact on Clinical Decision-making <b>2022</b> , 1, 129-136		
183	Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review protocol.. <i>BMJ Open</i> , <b>2022</b> , 12, e049713	3	0
182	Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0267124	3.7	
181	Gamma-Glutamyl Transferase (GGT) - an old dog with new tricks?. <i>Liver International</i> , <b>2021</b> ,	7.9	7
180	Liver Disorders Related to Alcohol and Other Drug Use <b>2021</b> , 1099-1111		0
179	Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
178	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. <i>Nature Communications</i> , <b>2021</b> , 12, 6105	17.4	3
177	Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. <i>JHEP Reports</i> , <b>2021</b> , 3, 100384	10.3	1
176	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
175	Increased case-finding and uptake of direct-acting antiviral treatment essential for micro-elimination of hepatitis C among people living with HIV: a national record linkage study. <i>HIV Medicine</i> , <b>2021</b> , 22, 334-345	2.7	
174	Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 909-915	3.4	
173	Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. <i>Addiction</i> , <b>2021</b> , 116, 2893-2907	4.6	9
172	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1896-1904	0.7	4
171	Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1246-1255	3.4	
170	Outcomes of the CT2 study: A one-stop-shop for community-based hepatitis C testing and treatment in Yangon, Myanmar. <i>Liver International</i> , <b>2021</b> , 41, 2578-2589	7.9	8
169	Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1744-1750	3.4	1

168	Identifying the Hidden Population: Former Intravenous Drug Users Who Are No Longer in Contact with Services. "Ask a Friend". <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	1
167	Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	3
166	Genome-Wide Association Study for Alcohol-Related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. <i>Gastroenterology</i> , <b>2020</b> , 159, 1276-1289.e7	13.3	19
165	Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?. <i>International Journal of Drug Policy</i> , <b>2020</b> , 82, 102811	5.5	1
164	Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2544-2553.e6	6.9	6
163	Effectiveness of the use of implementation intentions on reduction of substance use: A meta-analysis. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 214, 108120	4.9	7
162	Hepatitis C diagnosis and treatment, impact on engagement and behaviour of people who inject drugs, a service evaluation, the hooked C project. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 576-584	3.4	0
161	Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. <i>Gut</i> , <b>2020</b> , 69, 2223-2231	19.2	7
160	Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 1683-1690	5.6	6
159	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, e115-e124	11.6	28
158	Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 270-280	3.4	14
157	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 643-657	13.4	52
156	Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 809-818	18.8	24
155	Simplification of Care for Chronic Hepatitis C Virus Infection. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 392-402	7.3	12
154	Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real-world outcomes. <i>Health Science Reports</i> , <b>2020</b> , 3, e191	2.2	5
153	Reaching methadone users attending community pharmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV). <i>BMJ Open</i> , <b>2020</b> , 10, e036501	3	3
152	Intelligent Liver Function Testing: Working Smarter to Improve Patient Outcomes in Liver Disease. <i>Journal of Applied Laboratory Medicine</i> , <b>2020</b> , 5, 1090-1100	2	5
151	A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 765	2.9	26

150	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 245-253	6.1	35
149	Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 699-706	13.4	16
148	Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 425-434	6.1	3
147	Impact of Hepatitis C treatment on behavioural change in relation to drug use in people who inject drugs: A systematic review. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 169-176	5.5	21
146	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , <b>2019</b> , 156, 1707-1716.e2	13.3	59
145	Top research priorities in liver and gallbladder disorders in the UK. <i>BMJ Open</i> , <b>2019</b> , 9, e025045	3	13
144	Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , <b>2019</b> , 66, 73-79	5.5	20
143	Too many people with viral hepatitis are diagnosed late - with dire consequences. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 451-452	24.2	19
142	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 2218-2227	11.6	34
141	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). <i>BMJ Open</i> , <b>2019</b> , 9, e029538	3	16
140	We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. <i>Journal of Internal Medicine</i> , <b>2019</b> , 286, 503-525	10.8	39
139	Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNighly ColleCtion study for HCV treatment-ADVANCE HCV protocol <i>BMJ Open</i> , <b>2019</b> , 9, e029516	3	5
138	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , <b>2019</b> , 39, 20-30	7.9	49
137	High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 519-528	3.4	25
136	Application of a discrete choice experiment approach to support the design of a hepatitis C testing service in primary care. <i>International Journal of Drug Policy</i> , <b>2019</b> , 65, 1-7	5.5	7
135	New horizons in hepatitis B and C in the older adult. <i>Age and Ageing</i> , <b>2019</b> , 48, 32-37	3	3
134	Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 65-72	3.4	2
133	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 402-411	13.4	77

132	Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 930-938	3.4	9
131	Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the intelligent LFT pathway for the automated assessment of deranged liver enzymes. <i>Frontline Gastroenterology</i> , <b>2018</b> , 9, 175-182	2.6	7
130	Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2). <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2018</b> , 5, 367-398	7.9	101
129	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 153-161	18.8	155
128	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. <i>Seminars in Liver Disease</i> , <b>2018</b> , 38, 181-192	7.3	113
127	Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease. <i>Proteome Science</i> , <b>2018</b> , 16, 4	2.6	12
126	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , <b>2018</b> , 391, 1097-1107 <sup>40</sup>	4.0	90
125	The effect of low volume sprint interval training in patients with non-alcoholic fatty liver disease. <i>Physician and Sportsmedicine</i> , <b>2018</b> , 46, 87-92	2.4	3
124	The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 646-654	13.4	60
123	Guidelines on the management of abnormal liver blood tests. <i>Gut</i> , <b>2018</b> , 67, 6-19	19.2	180
122	Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. <i>BMJ Open</i> , <b>2018</b> , 8, e021443	3	8
121	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , <b>2018</b> , 62, 14-23	5.5	35
120	Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?. <i>Addiction</i> , <b>2018</b> , 113, 1727	4.6	22
119	Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 207-215	3.4	10
118	A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland. <i>Frontline Gastroenterology</i> , <b>2017</b> , 8, 221-228	2.6	22
117	The impact of rifaximin on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). <i>Frontline Gastroenterology</i> , <b>2017</b> , 8, 243-251	2.6	19
116	Limited impact of awareness-raising campaigns on hepatitis C testing practices among general practitioners. <i>Journal of Viral Hepatitis</i> , <b>2017</b> , 24, 944-954	3.4	9
115	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 137-144	13.4	78

114	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , <b>2017</b> , 152, 1078-1089	13.3	137
113	New metrics for the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , <b>2017</b> , 389, 2053-2080	2.2	1
112	Standing Outside the Junkie Door? Service users' experiences of using community pharmacies to access treatment for opioid dependency. <i>Journal of Public Health</i> , <b>2017</b> , 39, 846-855	3.5	9
111	Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 1391-1391h	7.8	17
110	Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis?. <i>Current Hepatology Reports</i> , <b>2017</b> , 16, 258-264	1	17
109	DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy. <i>International Journal of Drug Policy</i> , <b>2017</b> , 47, 126-136	5.5	37
108	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2017</b> , 47, 51-60	5.5	40
107	Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 19-27	13.4	37
106	The prevalence and impact of thrombocytopenia, anaemia and leucopenia on sustained virological response in patients receiving hepatitis C therapy: evidence from a large real world cohort. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 398-404	2.2	1
105	A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. <i>Journal of Viral Hepatitis</i> , <b>2016</b> , 23, 1009-1016	3.4	35
104	Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 145-56	6.1	8
103	Urgent action to fight hepatitis C in people who inject drugs in Europe. <i>Hepatology, Medicine and Policy</i> , <b>2016</b> , 1, 2		21
102	Gamma glutamyl transferase: to be or not to be? A liver function test?. <i>Annals of Clinical Biochemistry</i> , <b>2016</b> , 53, 629-631	2.2	10
101	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin. <i>Liver International</i> , <b>2016</b> , 36, 1295-303	7.9	35
100	Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs. <i>Drug and Alcohol Dependence</i> , <b>2016</b> , 165, 53-60	4.9	36
99	Health state utilities associated with attributes of treatments for hepatitis C. <i>European Journal of Health Economics</i> , <b>2015</b> , 16, 1005-18	3.6	30
98	Examination of methylglyoxal levels in an in vitro model of steatosis and serum from patients with non-alcoholic fatty liver disease. <i>Proceedings of the Nutrition Society</i> , <b>2015</b> , 74,	2.9	2
97	A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 27, 1-7	2.2	37



96	Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1041-9	5.5	22
95	The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: A systematic review of the literature. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 1050-5	5.5	63
94	Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. <i>Gut</i> , <b>2015</b> , 64, 1800-9	19.2	46
93	Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection. <i>Drug and Alcohol Dependence</i> , <b>2015</b> , 154, 125-31	4.9	13
92	HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. <i>Journal of Viral Hepatitis</i> , <b>2015</b> , 22, 399-408	3.4	77
91	Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , <b>2015</b> , 2, e000019	3.9	19
90	Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. <i>Hepatology</i> , <b>2015</b> , 62, 355-64	11.2	83
89	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , <b>2015</b> , 386, 2098-2111	4.0	47
88	What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 262-8	13.4	8
87	Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1839-47	4	29
86	Attendance at specialist hepatitis clinics and initiation of antiviral treatment among persons chronically infected with hepatitis C: examining the early impact of Scotland's Hepatitis C Action Plan. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 366-76	3.4	16
85	Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland. <i>Journal of Clinical Virology</i> , <b>2014</b> , 61, 359-64	14.5	32
84	Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. <i>BMJ Open</i> , <b>2014</b> , 4, e004837	3	19
83	Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1363-75	6.1	31
82	Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1118-26	13.4	18
81	Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. <i>Molecular and Cellular Biology</i> , <b>2014</b> , 34, 3305-20	4.8	141
80	Commentary: real-world triple therapy experience treating hepatitis C virus. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 542	6.1	1
79	Update on the treatment of hepatitis C genotypes 2-6. <i>Current Opinion in Infectious Diseases</i> , <b>2014</b> , 27, 540-4	5.4	6

78	Proteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 8325-40	5.6	26
77	Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach. <i>Frontline Gastroenterology</i> , <b>2013</b> , 4, 255-262	2.6	20
76	Commentary: assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 275	6.1	1
75	Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. <i>Hepatology</i> , <b>2013</b> , 57, 451-60	11.2	42
74	The diversity and management of chronic hepatitis B virus infections in the United Kingdom: a wake-up call. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 56, 951-60	11.6	30
73	Increasing survival of hepatocellular carcinoma patients in Scotland: a review of national cancer registry data. <i>Hpb</i> , <b>2013</b> , 15, 279-85	3.8	8
72	Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: association or causality?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 1084-92	6.1	134
71	Commentary: vancomycin or metronidazole in patients with primary sclerosing cholangitis?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 915	6.1	1
70	Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalization costs: a population record-linkage study in Tayside, Scotland. <i>Epidemiology and Infection</i> , <b>2013</b> , 141, 2122-30	4.3	2
69	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , <b>2013</b> , 58, 1598-609	11.2	366
68	Is travel-time to a specialist centre a risk factor for non-referral, non-attendance and loss to follow-up among patients with hepatitis C (HCV) infection?. <i>Social Science and Medicine</i> , <b>2012</b> , 75, 240-7	5.1	15
67	UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 647-62	6.1	66
66	Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. <i>PLoS ONE</i> , <b>2012</b> , 7, e39362	3.7	66
65	Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. <i>Journal of Viral Hepatitis</i> , <b>2012</b> , 19, 112-9	3.4	14
64	Spontaneous bacterial peritonitis prophylaxis in the era of healthcare associated infection. <i>Gut</i> , <b>2012</b> , 61, 1644-5	19.2	1
63	Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2012</b> , 24, 646-55	2.2	23
62	The effectiveness of outreach testing for hepatitis C in an immigrant Pakistani population. <i>Epidemiology and Infection</i> , <b>2012</b> , 140, 1048-53	4.3	15
61	The utility of liver function tests for mortality prediction within one year in primary care using the algorithm for liver function investigations (ALFI). <i>PLoS ONE</i> , <b>2012</b> , 7, e50965	3.7	12



60	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. <i>Gastroenterology</i> , <b>2011</b> , 141, 338-47	13.3	359
59	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using RVR. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1162-4; author reply 1164-6	13.4	6
58	The influence of hepatitis C and alcohol on liver-related morbidity and mortality in Glasgow injecting drug user population. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, e126-33	3.4	12
57	Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2011</b> , 31, 461-73	7.9	32
56	Bacterial translocation in cirrhosis is not caused by an abnormal small bowel gut microbiota. <i>FEMS Immunology and Medical Microbiology</i> , <b>2011</b> , 63, 346-54		16
55	Barrett's esophagus: proton pump inhibitors and chemoprevention I. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1232, 93-113	6.5	2
54	Does geographic access to primary healthcare influence the detection of hepatitis C?. <i>Social Science and Medicine</i> , <b>2011</b> , 72, 1472-81	5.1	21
53	Hospitalisation for an alcohol-related cause among injecting drug users in Scotland: increased risk following diagnosis with hepatitis C infection. <i>International Journal of Drug Policy</i> , <b>2011</b> , 22, 63-9	5.5	6
52	Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. <i>Hepatology</i> , <b>2011</b> , 54, 1547-58	11.2	48
51	Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006. <i>Epidemiology and Infection</i> , <b>2011</b> , 139, 344-53	4.3	13
50	The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 698-704	3.4	36
49	Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. <i>ClinicoEconomics and Outcomes Research</i> , <b>2010</b> , 2, 87-96	1.7	5
48	Diagnosis of hepatitis C virus infection in Scotland injecting drug user population. <i>Epidemiology and Infection</i> , <b>2010</b> , 138, 393-402	4.3	10
47	Hospitalization of hepatitis C-diagnosed individuals in Scotland for decompensated cirrhosis: a population-based record-linkage study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 49-57	2.2	13
46	Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. <i>Free Radical Biology and Medicine</i> , <b>2010</b> , 48, 357-71	7.8	190
45	Health outcomes following liver function testing in primary care: a retrospective cohort study. <i>Family Practice</i> , <b>2009</b> , 26, 251-9	1.9	19
44	A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. <i>Statistical Methods in Medical Research</i> , <b>2009</b> , 18, 271-83	2.3	41
43	Association of self-reported alcohol use and hospitalization for an alcohol-related cause in Scotland: a record-linkage study of 23,183 individuals. <i>Addiction</i> , <b>2009</b> , 104, 593-602	4.6	31

42	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <i>Nature Genetics</i> , <b>2009</b> , 41, 816-9	36.3	818
41	Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: a record-linkage population cohort study and decision analysis (ALFIE). <i>Health Technology Assessment</i> , <b>2009</b> , 13, iii-iv, ix-xi, 1-134	4.4	39
40	A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 805-10	8.7	15
39	Health-state utilities in liver disease: a systematic review. <i>Medical Decision Making</i> , <b>2008</b> , 28, 582-92	2.5	128
38	Minocycline hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2008</b> , 20, 796-9	2.2	22
37	Use of oesophageal stress response proteins as potential biomarkers in the screening for Barrett's oesophagus. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2008</b> , 20, 961-5	2.2	17
36	Microarray-formatted clinical biomarker assay development using peptide aptamers to anterior gradient-2. <i>Biochemistry</i> , <b>2007</b> , 46, 13742-51	3.2	30
35	Prevalence of laryngopharyngeal reflux in a population with gastroesophageal reflux. <i>Laryngoscope</i> , <b>2007</b> , 117, 1424-8	3.6	50
34	Microbial biofilms in the human gastrointestinal tract. <i>Journal of Applied Microbiology</i> , <b>2007</b> , 102, 1187-96	9.7	247
33	Development of a decision support tool to facilitate primary care management of patients with abnormal liver function tests without clinically apparent liver disease [HTA03/38/02]. Abnormal Liver Function Investigations Evaluation (ALFIE). <i>BMC Health Services Research</i> , <b>2007</b> , 7, 54	2.9	12
32	Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 29-38	11.6	159
31	Treatment of chronic transfusion-dependent gastric antral vascular ectasia (watermelon stomach) with thalidomide. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2006</b> , 18, 455-6	2.2	38
30	The calcium-binding domain of the stress protein SEP53 is required for survival in response to deoxycholic acid-mediated injury. <i>FEBS Journal</i> , <b>2006</b> , 273, 1930-47	5.7	24
29	The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. <i>Molecular and Cellular Proteomics</i> , <b>2004</b> , 3, 534-47	7.6	116
28	Hepatitis C: What is the best treatment?. <i>Journal of Viral Hepatitis</i> , <b>2004</b> , 11 Suppl 1, 23-7	3.4	18
27	Cirrhotic ascites: a review of management. <i>British Journal of Hospital Medicine</i> , <b>2004</b> , 65, 22-6		3
26	Alteration of glutathione S-transferase levels in Barrett's metaplasia compared to normal oesophageal epithelium. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2003</b> , 15, 41-7	2.2	11
25	The epidemiology of liver disease in Tayside database: a population-based record-linkage study. <i>Journal of Biomedical Informatics</i> , <b>2002</b> , 35, 186-93	10.2	16

24	Paracetamol-related deaths in Scotland, 1994-2000. <i>British Journal of Clinical Pharmacology</i> , <b>2002</b> , 54, 430-2	3.8	14
23	Paracetamol pack size restriction: the impact on paracetamol poisoning and the over-the-counter supply of paracetamol, aspirin and ibuprofen. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2002</b> , 11, 329-31	2.6	46
22	Paracetamol toxicity: epidemiology, prevention and costs to the health-care system. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2002</b> , 95, 609-19	2.7	75
21	Epidemiology and economic burden of viral hepatitis: an observational population based study. <i>Gut</i> , <b>2002</b> , 50, 100-5	19.2	22
20	The changing spectrum of gastroesophageal reflux disease. <i>European Journal of Cancer Prevention</i> , <b>2002</b> , 11, 215-9	2	14
19	The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 221-6	6.1	3
18	The human oesophageal squamous epithelium exhibits a novel type of heat shock protein response. <i>FEBS Journal</i> , <b>2001</b> , 268, 5343-55		37
17	Contractile response of isolated human hepatic arteries to $\beta$ adrenoceptor agonists is not impaired in patients with cirrhosis. <i>Clinical Science</i> , <b>1998</b> , 95, 505	6.5	8
16	Contractile response of isolated human hepatic arteries to $\beta$ adrenoceptor agonists is not impaired in patients with cirrhosis. <i>Clinical Science</i> , <b>1998</b> , 95, 505-511	6.5	7
15	Biochemical analysis of the stress protein response in human oesophageal epithelium. <i>Gut</i> , <b>1997</b> , 41, 156-63	19.2	31
14	The correction of autonomic dysfunction in cirrhosis by captopril. <i>Journal of Hepatology</i> , <b>1997</b> , 26, 331-5	13.4	32
13	A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. <i>Hepatology</i> , <b>1997</b> , 26, 1115-22	11.2	170
12	Platelet basal cytosolic calcium: the influence of plasma factors in cirrhosis. <i>Journal of Hepatology</i> , <b>1996</b> , 25, 312-5	13.4	7
11	Hypoxemia during diagnostic laparoscopy: a prospective study. <i>Gastrointestinal Endoscopy</i> , <b>1996</b> , 44, 124-8	5.2	15
10	Endoscopy. <i>Baillieres Clinical Gastroenterology</i> , <b>1995</b> , 9, 745-58		1
9	Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. <i>Journal of Hepatology</i> , <b>1995</b> , 22, 326-32	13.4	137
8	Middle cerebral artery blood flow velocity in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>1995</b> , 7, 1087-91	2.2	29
7	Regional survey on the management of oesophageal variceal haemorrhage. <i>Scottish Medical Journal</i> , <b>1995</b> , 40, 149-50	1.8	3

6	The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>1995</b> , 23, 254-8	13.4	53
5	Diagnostic laparoscopy and liver disease: experience of 200 cases. <i>Australian and New Zealand Journal of Medicine</i> , <b>1994</b> , 24, 258-62		15
4	Liver biopsy bleeding time: an unpredictable event. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1994</b> , 9, 269-71	4	33
3	Gastric mucosal bleeding time in cirrhosis. <i>Gastrointestinal Endoscopy</i> , <b>1994</b> , 40, 599-602	5.2	3
2	Autonomic function in cirrhosis assessed by cardiovascular reflex tests and 24-hour heart rate variability. <i>American Journal of Gastroenterology</i> , <b>1994</b> , 89, 1544-7	0.7	38
1	A Sustainable Development Goal framework to guide multisectoral action on NAFLD through a societal approach		1